New treatment for inflammatory bowel disease lands Microbiotica €42 million
Microbiotica, a British clinical-stage biopharma company developing a pipeline of orally-dosed, precision microbiome medicines, today announces the first close of a €42 million (£36 million) Series C financing. The financing was led by British Business Bank, with participation from Tencent, IP Group
<p>Microbiotica, a British clinical-stage biopharma company developing a pipeline of orally-dosed, precision microbiome medicines, today announces the first close of a €42 million (£36 million) Series C financing. The financing was led by British Business Bank, with participation from Tencent, IP Group</p>